iOMEDICO clinical trials
iOMEDICO is the lead sponsor of 17 current clinical trials in our Germany and Austria registers. 14 are recruiting patients now. All registered phases are Observational. The drugs named most often in its trials are Elacestrant, Obinutuzumab and Selinexor. The most-studied condition is Multiple Myeloma.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by iOMEDICO
17 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
NCT05326308 · ClinicalTrials.gov ↗ · Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma
Drugs: Obinutuzumab, Zanubrutinib |
Observational | Recruiting | 2022-04 | Germany, Austria |
|
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
NCT06607302 · ClinicalTrials.gov ↗ · Cholangiocarcinoma
|
Observational | Recruiting | 2024-10 | Germany |
|
Registry Platform Ovarian and Endometrial Cancer
NCT05129969 · ClinicalTrials.gov ↗ · Ovarian Cancer, Endometrial Cancer, Ovary Neoplasm
|
Observational | Recruiting | 2021-11 | Germany |
|
Research Platform Myelofibrosis and Anemia
NCT06976918 · ClinicalTrials.gov ↗ · Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
|
Observational | Recruiting | 2026-02 | Germany |
|
Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT06787105 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (mCRC)
|
Observational | Recruiting | 2025-02 | Germany |
|
Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma
NCT07240662 · ClinicalTrials.gov ↗ · Glioma
Drug: Vorasidenib |
Observational | Recruiting | 2025-12 | Germany |
|
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
NCT07559799 · ClinicalTrials.gov ↗ · Multiple Myeloma
|
Observational | Recruiting | 2026-06 | Germany |
|
Registry Platform Urologic Cancer
NCT03374267 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma, Urothelial Carcinoma
|
Observational | Recruiting | 2017-12 | Germany |
|
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
NCT06743035 · ClinicalTrials.gov ↗ · Polycythemia Vera
|
Observational | Recruiting | 2024-12 | Germany |
|
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
NCT07563595 · ClinicalTrials.gov ↗ · Breast Cancer
Drug: Elacestrant |
Observational | Recruiting | 2026-06 | Germany |
|
Breast Cancer Registry Platform
NCT03417115 · ClinicalTrials.gov ↗ · Breast Cancer
|
Observational | Recruiting | 2017-12 | Germany |
|
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
NCT06043011 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
|
Observational | Recruiting | 2023-09 | Germany |
|
Myeloma Registry Platform (MYRIAM)
NCT03308474 · ClinicalTrials.gov ↗ · Multiple Myeloma
|
Observational | Recruiting | 2017-09 | Germany |
|
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
NCT04290806 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
|
Observational | Recruiting | 2019-12 | Germany |
|
Registry Platform Colorectal Cancer
NCT04867525 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic
|
Observational | Active, closed | 2021-05 | Germany |
|
Liver Cancer Registry Platform
NCT04510740 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
|
Observational | Active, closed | 2020-08 | Germany |
|
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
NCT05954780 · ClinicalTrials.gov ↗ · Multiple Myeloma
Drug: Selinexor |
Observational | Active, closed | 2023-06 | Germany, Austria |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in iOMEDICO trials
5 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in iOMEDICO trials
30 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Germany | 17 | 14 |
| Clinical trials in Austria | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Multiple Myeloma
Sponsors with the most current trials registered for this condition.
Questions about iOMEDICO trials
How many clinical trials does iOMEDICO sponsor?
iOMEDICO is the lead sponsor of 17 current trials on ClinicalTrials.gov in our Germany and Austria registers, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.
Are iOMEDICO trials recruiting?
Yes. 14 of its 17 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is iOMEDICO testing?
Its current trials name 5 drugs and biologicals as interventions. The most frequent are Elacestrant (1), Obinutuzumab (1), Selinexor (1), Vorasidenib (1) and Zanubrutinib (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.